Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Therapeutic Advances in Hematology|August 15, 2022
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerationsAlexandra R Lovell, Nadya Jammal, Prithviraj Bose
Best Practice & Research. Clinical Haematology|December 6, 2020
Antibody based therapy in relapsed acute lymphoblastic leukemiaNadya Jammal, Serena Chew, Elias Jabbour, et al.
Best Practice & Research. Clinical Haematology|December 6, 2020
Monoclonal antibodies in frontline acute lymphoblastic leukemiaSerena Chew, Nadya Jammal, Hagop Kantarjian, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 20, 2019
Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective studyNadya Jammal, Eva Pan, Michael Hurwitz, et al.
Expert Opinion on Emerging Drugs|November 9, 2020
Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trialsNadya Jammal, Caitlin R Rausch, Tapan M Kadia, et al.
Clinical Advances in Hematology & Oncology : H&O|January 6, 2023
Management of acute lymphoblastic leukemia in older adultsNadya Jammal, Hagop M Kantarjian, Fadi Haddad, et al.
British Journal of Haematology|May 11, 2021
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemiaHua-Jay J Cherng, Nadya Jammal, Shilpa Paul, et al.
American Journal of Hematology|June 17, 2022
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>-4</sup> and higherElias J Jabbour, Nicholas J Short, Nitin Jain, et al.
Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.
Pageof 1